Safety and Efficacy Study Using Rexin-G for Breast Cancer

Summary

The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol for recurrent or metastatic breast cancer.

Timeline

Start

2007-07

Primary completion

2010-07

Completion

2011-06

Drugs

Indications